ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc.

May 06, 2011 17:16 ET

ProMetic Provides Corporate Update and Information Regarding Its Upcoming AGM

- AGM to be held on May 18, 2011

- UK parliamentary minutes regarding variant Creutzfeldt-Jakob disease ("vCJD")

- Q1 2011 financial statements to be published on June 14, 2011

- New investor relations contact

MONTREAL, QUEBEC, CANADA--(Marketwire - May 6, 2011) -ProMetic Life Sciences Inc. ("ProMetic") (TSX:PLI) will host its Annual Meeting of Shareholders ("AGM") on Wednesday, May 18, 2011 at 10:30 a.m. (EDT) in Salon 3, Level 2 of the Centre Sheraton Montreal Hotel, located at 1201 René-Lévesque Blvd. West, Montreal.

The AGM will be followed by a corporate presentation which will highlight the progress made with respect to ProMetic's small molecule therapeutics program and regarding its plasma derived therapeutics business; namely with respect to Wuhan Institute of Biologic Products / China National Biotech Group. Details regarding Prometic's new plasma protein manufacturing facility and its impact on future growth for the Company will also be discussed. Shareholders will receive an update regarding ProMetic's prion removal technology / PCapt® filter adoption. The UK government released minutes regarding parliamentary discussions held with respect to implementing precautionary measures (including PCapt® filter) to avoid prion infection / vCJD. To read the full text, go to:

For those who are unable to attend in person, the Company will offer a live audio conference call and web cast through ProMetic's website on the Events page - and in the Highlights section of the Home page - The numbers to access the conference call are (416) 981-9000 (international) and 1 (800) 742-6164 (North America toll free).

An audio replay of the call will be available for a period of seven days as of Wednesday, May 18, 2011 at 15:00 (EDT). The numbers to access the audio replay are (416) 626-4100 (international) and 1 (800) 558-5253 (North America toll free) using access code 21517828. The replay of the web cast may be downloaded directly from ProMetic's web site.

In accordance with the provisions of section 14.3 of National Instrument 51-102 Continuous Disclosure Requirements, the Company will be taking the offered transitional 30-day filing extension for its March 31, 2011 interim report, on the basis that it is disclosing, for the first time, a statement of compliance with International Accounting Standard 34 Interim Financial Reporting. As a result the Company intends to file its first quarter report on June 14, 2011.

We are also pleased to announce that Mr. Frédéric Dumais will be joining ProMetic Life Sciences on May 9, 2011 as Director, Communications and Investor Relations (IR). Mr. Dumais is a seasoned IR professional with several years of experience in the telecommunication and biotechnology industries. Mr. Dumais replaces Ms. Anne Leduc. Mr. Dumais contact information as of May 9, 2011 shall be: Tel: 1+ 450-781-0115, extension 2234; E-mail:

About ProMetic Life Sciences Inc.

ProMetic Life Sciences Inc. ("ProMetic") ( is a biopharmaceutical company specialized in the research, development, manufacture and marketing of a variety of commercial applications derived from its proprietary Mimetic Ligand™ technology. This technology is used in large-scale purification of biologics and the elimination of pathogens. ProMetic is also active in therapeutic drug development with the mission to bring to market effective, innovative, lower cost, less toxic products for the treatment of hematology and cancer. Its drug discovery platform is focused on replacing complex, expensive proteins with synthetic "drug-like" protein mimetics. Headquartered in Montréal (Canada), ProMetic has R&D facilities in the UK, the US and Canada, manufacturing facilities in the UK and business development activities in the US, Europe, Asia and in the Middle-East.

Contact Information